STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Stoke Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$24.82+0.65 (+2.69%)
Close on Oct 19, 2026
- Market cap
- $1.64B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Operating margin
-11.2%
Net margin
-3.7%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +404.5% | +145.9% | – | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -20.5% | -2.4% | |
| Return on assets | – | -19.8% | -2.0% | |
| Current ratio | – | 25.73 | 5.28 | |
| Interest coverage | – | – | -2287.8× | |
| Capex to revenue | – | – | 0.4% | |
| Diluted shares | – | 33M | 59M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Stoke Therapeutics generated $312.28M from operations and spent $7.65M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$312.28M
Used
$7.65M
Capital expenditure$7.65M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-3.7%
×Asset turnover0.53×
×Equity multiplier1.19×
=Return on equity, FY2025-2.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -3.7% | 0.53× | 1.19× | -2.4% |
| FY2024 | -243.4% | 0.15× | 1.29× | -45.8% |
| FY2023 | -1192.5% | 0.04× | 1.41× | -60.8% |
| FY2022 | -814.7% | 0.05× | 1.23× | -50.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$6.89M
- Cash generatingOperating cash flow above zero$45.59M
- Return on assets improvedROA up on the prior year-39.0% → -2.5%
- Earnings backed by cashOperating cash flow above net income$45.59M vs -$6.89M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.81 → 5.28
- No dilutionShare count did not rise54M → 59M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.16 → 0.68